Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT plus apatinib versus whole brain radiotherapy for patients with more than 4 brain metastases
ChiCTR1800019256Phase 2Completed
- Sponsor
- Wuhan Central Hospital
- Start
- Dec 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in brain metastases (2 arms), sponsored by Wuhan Central Hospital. Primary endpoint: intracranial progression-free survival. Started Dec 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
brain metastases
Beyond the preview
Go deeper on ChiCTR1800019256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019256.